Business
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V:...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities\n\n\n\n VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that members of its executive team will attend the 2025 BIO International Convention, taking place June 16\n \n th\n \n – 19\n \n th\n \n in Boston, Massachusetts.\n \n\n Rakovina Therapeutics’ management will participate in one-on-one partnering meetings throughout the conference with leading global pharmaceutical and biotechnology companies.\n \n\n The Company will showcase its pipeline of novel DNA damage response (DDR) inhibitors, including drug candidates discovered through its proprietary AI-driven platforms—Deep Docking and Variational AI’s generative technology. These collaborations have produced promising compounds with potential applications in DDR-targeted oncology therapies, including candidates capable of penetrating the blood-brain barrier and addressing significant unmet medical needs in the treatment of cancer.\n \n\n KT-3000 Series\n \n\n The KT-3000 series is a novel class of dual-function small molecule inhibitors combining PARP and histone deacetylase (HDAC) inhibition in a single agent. Published pre-clinical data demonstrate that lead candidates for the kt-3000 series retain anti-tumor activity in cancers that are resistant to treatment with FDA-approved PARP inhibitors. The KT-3000 program presents an attractive partnering opportunity for companies seeking to expand their oncology portfolios with multi-functional agents that can be developed across a range of solid tumor indications. Rakovina is actively exploring collaborations to accelerate development and broaden the clinical utility of this program.\n \n\n KT-2000AI Series\n \n\n The KT-2000 series features highly selective PARP1 inhibitors designed to penetrate the blood-brain-barrier, addressing a critical unmet need in the treatment of primary and metastatic brain tumors. The Company previously announced that it had used its proprietary AI algorithm to screen billions of potential drug candid...